KR101398549B1 - A composition for skin disease improvement comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient - Google Patents
A composition for skin disease improvement comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient Download PDFInfo
- Publication number
- KR101398549B1 KR101398549B1 KR1020120080623A KR20120080623A KR101398549B1 KR 101398549 B1 KR101398549 B1 KR 101398549B1 KR 1020120080623 A KR1020120080623 A KR 1020120080623A KR 20120080623 A KR20120080623 A KR 20120080623A KR 101398549 B1 KR101398549 B1 KR 101398549B1
- Authority
- KR
- South Korea
- Prior art keywords
- fraction
- extract
- acne
- active ingredient
- centipede
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 102
- 241000025852 Eremochloa ophiuroides Species 0.000 title claims abstract description 69
- 239000004480 active ingredient Substances 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 208000017520 skin disease Diseases 0.000 title abstract description 49
- 230000006872 improvement Effects 0.000 title description 12
- 206010000496 acne Diseases 0.000 claims abstract description 62
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 60
- 208000001840 Dandruff Diseases 0.000 claims abstract description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 90
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- 241000258920 Chilopoda Species 0.000 claims description 31
- 239000003960 organic solvent Substances 0.000 claims description 30
- 239000011521 glass Substances 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 25
- 238000004440 column chromatography Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 239000002537 cosmetic Substances 0.000 claims description 13
- 235000013402 health food Nutrition 0.000 claims description 10
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 210000004209 hair Anatomy 0.000 claims description 7
- 239000000344 soap Substances 0.000 claims description 6
- 239000002453 shampoo Substances 0.000 claims description 5
- 230000001256 tonic effect Effects 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims 5
- 241000894006 Bacteria Species 0.000 abstract description 21
- 241000555676 Malassezia Species 0.000 abstract description 11
- 208000020154 Acnes Diseases 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 231100000676 disease causative agent Toxicity 0.000 abstract description 5
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 19
- 241000186427 Cutibacterium acnes Species 0.000 description 17
- 244000025254 Cannabis sativa Species 0.000 description 15
- 241000191963 Staphylococcus epidermidis Species 0.000 description 14
- 229940055019 propionibacterium acne Drugs 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000007796 conventional method Methods 0.000 description 10
- 239000000401 methanolic extract Substances 0.000 description 10
- 239000002032 methanolic fraction Substances 0.000 description 10
- 210000001732 sebaceous gland Anatomy 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- -1 RP-18 Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000003780 hair follicle Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 241000555688 Malassezia furfur Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 210000002374 sebum Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 241001112696 Clostridia Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- ZDWVWKDAWBGPDN-UHFFFAOYSA-O propidium Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZDWVWKDAWBGPDN-UHFFFAOYSA-O 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001522296 Erithacus rubecula Species 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 241000206609 Porphyra Species 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000012754 barrier agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- LVQSCKUKDKAQGO-UHFFFAOYSA-L disodium;diiodide Chemical compound [Na+].[Na+].[I-].[I-] LVQSCKUKDKAQGO-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HSSGNVITVKZRHD-UHFFFAOYSA-L magnesium octadecanoate octadecanoic acid Chemical compound [Mg++].CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HSSGNVITVKZRHD-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- WNKAKXXEMWUMHN-UHFFFAOYSA-M sodium;dodecanoate;propane-1,2,3-triol Chemical compound [Na+].OCC(O)CO.CCCCCCCCCCCC([O-])=O WNKAKXXEMWUMHN-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 질환 개선용 조성물에 관한 것으로 더욱 상세하게는 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획이 여드름균의 원인균인 표피 포도구균 및 프로피로니박테리움 아크네스, 및 비듬의 원인균인 말라세지아의 성장을 현저히 저해시킴으로서 새로운 천연 여드름 등을 포함한 미생물 유해의 피부질환을 효과적으로 예방, 치료 및 개선에 유용하게 사용될 수 있다. The present invention relates to the use of Centipede grass ( Eremochloa ophiuroides extract or a fraction thereof as an active ingredient. More particularly, the present invention relates to a composition for improving skin diseases, which comprises extracts of Sentifedgrass , fractions thereof, or active fractions isolated from the fractions, Ronni Bacterium acnes, and Malassezia, a causative agent of dandruff, can be effectively used to effectively prevent, treat and improve skin diseases of microbial harmful substances including new natural acne.
Description
본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 질환 개선용 조성물에 관한 것이다.
The present invention relates to the use of Centipede grass ( Eremochloa ophiuroides extract or a fraction thereof as an active ingredient.
여드름(acne vulgaris)은 15세에서 40세 사이에 발생하는 피부질환으로, 특히 사춘기에 흔한 질환으로 알려져 있다. 주로 얼굴, 가슴, 등, 어깨 등에 발생하는 폐쇄성(whiteheads) 또는 개방성(blackheads), 면포(comedo), 구진(papule), 농포(pustule), 결절(nodule) 등의 병변을 특징으로 하는 모피지선에서 발생하는 만성 염증성 질환으로 정의된다. 여드름의 종류로는 흔히 보는 여드름으로서 보통 여드름이 있는데, 이는 심상성 여드름이라고도 하며, 특징으로는 전형적인 면포와 여러 종류의 발진이 섞여 나타난다. 켈로이드성 여드름(acne keloidalis)은 고름 같은 분비물이 여기저기서 분출되는 큰 농양이나 고름 주머니, 그리고 염증성 결절 등이 특징적으로 나타나는데 여드름 중 가장 심한 형태에 속한다. 월경이 시작되기 약 일주일 전에 기존의 여드름이 심해지는 월경 전 여드름(premenstrual acne), 태아시기에 모체로부터 받은 호르몬 중 프로게스테론이 피지선의 분비를 자극하기 때문에 발생하는 신생아 여드름(preadolescent acne)이 있고, 그 외에 입 주위 여드름, 성인형 여드름 등이 있다. 10대의 경우 90%에서 다양한 정도의 여드름을 가지고 있다고 알려져 있으나, 공기 오염, 약물 남용 등으로 근래에는 나이와 상관없이 발생하여 여드름이 생기는 연령층이 넓어지고 있다. 여드름의 발생에는 다양한 요인들이 영향을 미치는 것으로 밝혀져 있으며, 그 중 대표적인 4 가지 요소, 즉 비정상적인 모낭이상 각화, 피지 분비의 증가, 여드름균인 프로피오니박테리움 아크네스(Propionibacterium acnes, P. acnes)로 대표되는 세균의 증식, 이로 인한 염증 유발이 중요하게 꼽힌다 (오성문, 약용식물로부터 여드름 원인 미생물에 대한 천연 항균제 탐색, 연세대 공학대학원 석사논문, 2006).
Acne vulgaris is a skin disease that occurs between the ages of 15 and 40, especially acne vulgaris. The fur branch line, which is characterized by lesions such as whiteheads or blackheads, comedo, papule, pustule, nodule, and the like occurring mainly on the face, chest, back, shoulder, Is defined as a chronic inflammatory disease that occurs. The most common type of acne is acne, which is usually called acne, and it is characterized by a mixture of typical cotton wool and various types of rashes. Keloid acne (acne keloidalis) is characterized by a large abscess, pus, and inflammatory nodules, which are pus-like discharges from the pus-like secretions, and are among the most severe of acne. Premenstrual acne is a premenstrual acne in which the existing acne gets worse about a week before menstruation begins. There is a preadolescent acne that occurs because the progesterone stimulates the secretion of sebaceous glands from the maternal hormones in the fetal period. In addition to acne around the mouth, adults have acne. It is known that 90% of teenagers have various degrees of acne. However, due to air pollution, substance abuse and the like, it is widespread among the age group that acne occurs regardless of age. It has been shown that various factors influence the occurrence of acne, and the four most common factors are abnormal keratinization, increased sebum secretion, and acne bacterium Propionibacterium acnes (P. acnes). It is important to proliferate the representative bacteria and to induce inflammation (Oh Sung Moon, Exploring Natural Antimicrobial Agents for Acne Causing Acne from Medicinal Plants, Master's Thesis, Yonsei University Graduate School, 2006).
예전에는 여드름의 발생이 당연한 성장 과정이나 체질로 여겨졌으나, 최근에는 관심을 가지고 적극적으로 관리 또는 치료하기를 원하는 사람들이 늘고 있다. 대부분의 피부 트러블은 생명 유지에는 지장이 없지만, 대인관계 및 일상생활에 심리적인 영향을 미친다. 특히, 여드름은 다른 질환과는 달리 외부로 노출되고 때로는 직접 만져질 수도 있으므로 다른 내과적 문제보다도 더 심각하게 느낄 수 있다. 더구나 청소년기뿐만 아니라 성인이 되어서도 지속되는 질환이기 때문에 많은 현대인들이 겪는 피부트러블 중의 하나이다 (오혜영 등, 여고생들의 여드름 인식에 대한 연구, 한국미용학회지 14(1), 124-133, 2008).
In the past, the occurrence of acne was considered natural growth or constitution, but in recent years, more and more people are interested in actively managing or treating them. Most skin troubles do not interfere with life support, but they have a psychological impact on interpersonal and daily life. In particular, acne can be felt to be more serious than other medical problems because it can be exposed to the outside and sometimes touched directly, unlike other diseases. In addition, it is one of the skin troubles suffered by many modern people because it is a disease that continues to be an adult as well as an adolescent. (Oh Hye-young et al., A Study on Acne Recognition by High School Girls, Korean Journal of Hairdressing 14 (1), 124-133, 2008).
여드름의 발생 기전을 살펴보면 다음과 같다. 사춘기가 되면 남녀 모두 남성호르몬 분비가 왕성해져서 모낭 옆에 붙어있는 피지선을 자극하게 되고 그 결과 피지선이 커져 많은 피지가 분비된다. 이와 동시에 털구멍, 즉 모공 입구의 각질층이 두꺼워지고 접착력이 높아져 모공이 좁아지거나 막히게 된다. 그 결과 모낭 내에 피지가 쌓이고 모낭 내에 살고 있던 세균이 번식하여 염증으로 발전하는데 이렇게 염증으로 발전한 것이 여드름이다. 근본적으로 피지선을 자극하는 남성호르몬인 안드로겐과 모피지선(毛皮脂腺)에서 번식하여 피지를 분해, 유리지방산을 생성하고 프로피오니박테리움 아크네스가 작용하여 생긴다 (신경훈등, 피지생성과 여드름, 한국피부장벽학회 10(1), 56-60, 2008).
The mechanism of the occurrence of acne is as follows. In puberty, both men and women become vigorous in male hormone secretion, stimulating the sebaceous glands attached to the hair follicles. As a result, sebaceous glands are enlarged and many sebum are secreted. At the same time, the pores of the pores, that is, the stratum corneum of the pore mouth, become thick and the pores become clogged or clogged due to the increased adhesion. As a result, sebaceous glands accumulate in the hair follicles and the bacteria that live in the hair follicles develop into inflammation. It is basically produced by the production of free fatty acids and the production of propionibacterium acnes in the production of androgen and sebaceous glands, which are male hormones that stimulate sebaceous glands and break down the sebaceous glands (sebaceous glands and acne, Korean skin Barrier Society 10 (1), 56-60, 2008).
프로피오니박테리움 아크네스 외에 일반적인 피부 상재균 중 피부에 염증을 유발할 수 있는 세균으로는 스타필로코시 에피더미디스(S. epidermidis), 말라세지아 푸르푸르 등이 보고되어 있다. 한편, 여드름 병변에서 분리되는 대표적인 세균은 프로피오니박테리움 아크네스이지만, 스타필로코시 에피더미디스와 같은 다른 균들도 분리되는 것으로 보고되고 있다. 말라세지아(Malassezia) 속의 균들은 오랫동안 피부에 서식하는 균류로, 특정 조건에서 피부 등의 표면 감염을 일으키는 원인이 될 수 있고 이식환자 등에서는 기회주의 병원체가 될 수 있다 (손호용 등, 피부 여드름 치료제 개발을 위한 천연물의 항균활성 검색, 한국미생물생명공학회지 34(3), 265-272, 2006).
In addition to Propionibacterium acnes, S. epidermidis and Malassezia furfur have been reported as common bacteria that can cause inflammation in skin. On the other hand, a representative bacterium isolated from acne lesions is Propionibacterium acnes, but other fungi such as Staphylococcus epidermidis are also reported to be isolated. Malassezia spp. Are fungi that live on the skin for a long time, which can cause surface infections of the skin under certain conditions, and can become an opportunistic pathogen in transplant patients (eg, , Journal of Microbiology and Biotechnology, 34 (3), 265-272, 2006).
프로피오니박테리움 아크네스는 그람 양성 혐기성 세균으로 0.3 ~ 1.3 ㎛ ×1 ~ 10㎛이고 균체 일부가 팽대하며 균단은 뾰족하고 다형성이고 V자 배열을 하고 있다. 정상 성인의 피지선에서 80%까지 검출되는 정상 균총의 하나이나 피지분비가 많은 모공 주변 등에 분포하며 표피성 포도상 구균과 함께 피부에 존재하면서 여드름 등과 같은 모낭염 등 피부질환을 발생과 증상을 악화시키는 원인균이 되기도 한다. 프로피오니박테리움 아크네스는 피지를 주 영양원으로 하며, 피지의 주성분인 중성지방을 지방산과 글리세롤로 분해하며, 이때 생성된 유리 지방산은 피부에 심한 자극을 주어 모낭벽이나 모공 주위에 세포에 염증을 일으킨다. 또한 이 균에 의해 자극을 받은 상피세포는 각질세포 생성이 증가하여 정체 과각화가 이루어져 여드름의 초기단계인 미세면포를 형성하며, 계속하여 각질과 피지가 분해됨으로서 모낭 벽이 얇아지고, 프로피오니박테리움 아크네스를 탐식한 백혈구가 분비하는 가수분해효소의 작용에 의해 모낭 벽이 파열되고 모근 내용물이 진피내로 유리되어 염증반응이 가속화된다 (이경숙 등, 여드름병변에서 채취한 프로피오니박테리움 아크네스의 분리, 동정 및 생화학적 특정 연구, 한국의류산업학회지 8(5), 571-576, 2006).
Propionibacterium acnes is a gram-positive anaerobic bacterium with a size of 0.3 to 1.3 ㎛ × 1 to 10 ㎛, and a part of the microbial cells are swollen with a sharp pointed polymorphism and a V-shaped arrangement. It is distributed in the vicinity of normal papillary glands of normal adults, which is detected in up to 80% of normal papillomas or sebaceous glands with many sebaceous secretions. It is present in the skin along with epidermal staphylococci and causes skin diseases such as acne and folliculitis. It is. Propionibacterium acnes is the main nutrient source of sebum, and it decomposes triglycerides, the major component of sebum, into fatty acids and glycerol. The resulting free fatty acids cause severe irritation to the skin, causing inflammation of the cells around the hair follicle wall and pores. Cause. In addition, the epithelial cells stimulated by the bacterium are increased in keratinocyte production, resulting in congestion, forming microcapsules, which are early stages of acne, and subsequently keratin and sebum are degraded, resulting in thinning of the hair follicle wall, The hair follicle wall ruptures and the contents of the hair follicles are released into the dermis by the action of the hydrolytic enzymes secreted by the white blood cells digested by the acnes, thereby accelerating the inflammatory reaction (Lee, Kyung-Sook et al., Separation of propionibacterium acnes from acne lesions , Identification and biochemical specific study, Journal of the Korean Society of Clothing Industry 8 (5), 571-576, 2006).
스타필로코시 에피더미디스(S. epidermidis)는 그람양성 세균에 속하는 스타필로코시(Staphylococcus) 속 중 하나이다. 스타필로코시 에피더미디스의 콜로니는 일반적으로 작고, 흰색에서 노란색이며, 철야(overnight) 배양 후 지름 1 ~ 2 mm 정도로 자란다. 사람과 동물의 피부에서 자주 발생하며, 점막에서도 나타난다. 호기성 호흡이나 발효에 의해 성장하며 혐기성에서도 생존할 수 있다. 항생제인 노보비오신(Novobiocin)에 민감하나, 페니실린(penicillin)과 메티실린(methicillin) 등의 다양한 항생제에는 내성이 있다. 스타필로코시 에피더미디스는 일반적으로 비병원성 균이지만 면역계나 유치(留置)도뇨관 환자에게는 감염을 일으키는 주요한 원인이 된다. 많은 변종들은 의료 보철물의 표면에 접착하여 균막을 형성한다 (장영식 등, 스타필로코시 에피더미디스 각막염의 역학조사, 대한안과학회지 43(4), 665-671, 2002).Staphylococcus epidermidis is one of the Staphylococcus belonging to gram-positive bacteria. Colonies of Staphylococcus epidermidis are generally small, white to yellow, and grow to 1-2 mm in diameter after overnight culture. It occurs frequently in human and animal skin and also in mucous membranes. It grows by aerobic respiration or fermentation and can survive in anaerobic conditions. It is sensitive to the antibiotic novobiocin, but it is resistant to various antibiotics such as penicillin and methicillin. Staphylococcus epidermidis is generally a non-pathogenic bacterium, but it is a major cause of infection in patients with immune system or indwelling catheters. Many variants adhere to the surface of the medical prosthesis to form a bacterium (Chang et al., Epidemiology of staphylococci epidermidis keratitis, Korean Ophthalmological Society 43 (4), 665-671, 2002).
말라세지아 푸르푸르(Malassezia furfur, M. furfur)는 두꺼운 다층의 세포벽을 가지는 다형태의 친지방성 미생물로 콜로니는 작고 황갈색이며 선명한 테두리를 가지고 있다. 말라세지아 푸르푸르는 이스트에 속하며, 보통 인간을 포함한 동물 피부 표면에 있다. 감염이 되면 등이나 가슴 부위의 저색소침착증(hypopigmentation)이 일어날 수 있다. 생존하기 위해서는 지방이 필요하며, 따라서 머리가죽, 얼굴, 상반신 등의 대부분이 피지선에 흔하게 존재한다. 자라는 속도가 너무 빠를 때는 세포의 자연 재생이 흐트러져 긁으면 비듬이 발생한다 (김영주 등, 용뇌향(Dryobalanops aromatica) 유래 용뇌의 말라세지아 푸르푸르에 대한 항균 활성, 한국미생물생명공학회지 33(3), 236-239, 2005).
Malassezia furfur (M. furfur) is a multifactorial lipophilic microorganism with a thick multi-layered cell wall. Its colonies are small, yellowish brown and have sharp edges. Malassezia furfur is a yeast belonging to the skin surface of animals, usually humans. Infection can lead to hypopigmentation of the back or chest area. To survive, fat is needed, and therefore most of the hair, face, and upper body are commonly found in sebaceous glands. When the rate of growth is too fast, the natural reproduction of the cells is disturbed, resulting in dandruff if scratched (Kim, Young-Ju et al., Antimicrobial Activity against Malassezia furfur from Driobalanops aromatica, Korean Society of Microbial Biotechnology, 33 -239, 2005).
센티페드그라스(Centipede grass, Eremochloa ophiuroides)는 생육이 늦은 난지형 잔디로서 뗏장을 형성하며 포복 생장을 하는 다년생 잔디이다. 벼과 식물에 속하며, 학명은 Eremochloa ophiuroides (Munro) Hack이다. 주로 중국과 동아시아, 인도차이나, 미국 북동부, 메소아메리카와 캐러비안 지역에 분포하고 있으며, 각종 토양조건에 폭 넓게 잘 적응되지만, 특히 습하며 산성토양 및 비옥도가 낮은 사질 토양에서 잘 견딘다.Centipede grass ( Eremochloa ophiuroides ) is a perennial turf that grows slowly and forms a turf as a turfgrass. It belongs to the genus Porphyra, and its scientific name is Eremochloa ophiuroides (Munro) Hack. It is mainly distributed in China, East Asia, Indochina, Northeastern USA, Mesoamerica and the Caribbean. It is well adapted to various soil conditions, but it is particularly resistant to moist and acid soil and low fertility soil.
형태학적 특징으로서, 잎은 길이 15~30 ㎜, 폭 2~4 ㎜이고, 흰 중심맥(mid vein)을 가지는 납작한 모양이며, 경령(collar) 부분을 제외하고 털이 없고, 잎 끝부분은 둥글다. 줄기는 아주 굳게 다문 잎집(sheath)을 가지고, 뿌리는 가는 분기형의 포복경(stolons)이다. 꽃 부분은 3~5 인치 정도의 하나의 총상화서(總狀花序, raceme, = 총상꽃차례)를 가지고, 상기 총상화서는 자줏빛색을 띠고 약간 평평하며 두 줄로 배열된 작은 이삭(小穗, spikelet)을 가진다. 주용도는 잔디 밭 또는 뗏장 잔디로 사용되고 높은 잎의 비율(leafiness)과 좋은 맛 때문에 조사료로 이용된다.
As a morphological feature, the leaf has a length of 15 ~ 30 ㎜, a width of 2 ~ 4 ㎜, a flat shape with a mid vein, no hairs except a collar part, and a leaf tip round. The stem is a branching type stolons with a very firmly sheath (sheath). The flower part has a three to five inches long fossil flower (raceme), which has a purple color and a slightly flat, spikelet arranged in two lines. I have. It is used as a lawn or turf grass and is used as a forage for its leafiness and good taste.
이에 본 발명자들은 독성이 없고 여드름 원인균의 성장을 저해시킴으로서 피부 질환 개선을 효과를 갖는 천연 식물 추출물을 연구하던 중, 센티페드그라스에서 추출한 추출물, 이의 분획물 및 상기 분획물로부터 분리한 활성분획이 여드름균의 원인균인 표피 포도구균 및 프로피로니박테리움 아크네스, 및 비듬의 원인균인 말라세지아의 성장을 현저히 저해시킴으로 피부 질환 개선용 조성물의 유효성분으로 유용하게 사용될 수 있음을 밝힘으로서 본 발명을 완성하였다.
Accordingly, the inventors of the present invention studied natural plant extracts having no toxicity and inhibiting the growth of acne causative microorganisms and having an effect of improving skin diseases, and found that extracts from centipedegrass, their fractions, and the active fractions isolated from the fractions, The present invention has been accomplished based on the discovery that it can be effectively used as an effective ingredient of a composition for improving skin diseases by significantly inhibiting the growth of Staphylococcus epidermidis, Propionibacterium acnes, causative bacteria, and Malassezia, a causative agent of dandruff.
본 발명의 목적은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 질환 개선용 조성물을 제공하는 것이다.
It is an object of the present invention to provide a composition for the improvement of skin diseases containing Centipede grass ( Eremochloa ophiuroides ) extract or a fraction thereof as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 피부질환 예방 및 치료용 약학적 조성물을 제공한다. In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing and treating skin diseases, which contains Centipede grass ( Eremochloa ophiuroides ) extract as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 피부질환 예방 및 치료용 약학적 조성물을 제공한다.The present invention also provides a pharmaceutical composition for preventing and treating skin diseases, which comprises an organic solvent fraction prepared by further extracting a centipedragus extract with an organic solvent as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 피부질환 예방 및 치료용 약학적 조성물을 제공한다. The present invention also provides a pharmaceutical composition for the prevention and treatment of skin diseases, which comprises an active fraction obtained by further fractionating a fraction of Sentifedgrass extract by column chromatography, as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 피부질환 개선용 화장료 조성물을 제공한다. In order to achieve the above object, the present invention provides a cosmetic composition for improving skin diseases, which contains Centipede grass ( Eremochloa ophiuroides ) extract as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 피부질환 개선용 화장료 조성물을 제공한다. The present invention also provides a cosmetic composition for skin disease improvement comprising an organic solvent fraction prepared by further extracting a centipedragus extract with an organic solvent as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 피부질환 개선용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for skin disease improvement comprising an active fraction obtained by further fractionating a fraction of Sentifed glass extract by column chromatography as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 피부질환 예방 및 치료용 피부 외용제를 제공한다. In order to achieve the above object, the present invention provides an external preparation for skin for preventing and treating skin diseases, which comprises Centipede grass ( Eremochloa ophiuroides ) extract as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 피부질환 예방 및 치료용 피부 외용제를 제공한다. The present invention also provides an external preparation for skin for preventing and treating skin diseases, which comprises an organic solvent fraction prepared by further extracting a centipede glass extract with an organic solvent as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 피부질환 예방 및 치료용 피부 외용제를 제공한다. The present invention also provides an external preparation for skin for the prevention and treatment of skin diseases, which comprises an active fraction obtained by further fractionating a fraction of Sentifedgrax extract by column chromatography.
상기 목적을 달성하기 위하여, 본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 피부질환 개선용 건강식품을 제공한다. In order to achieve the above object, the present invention provides a health food for improving skin diseases, which contains Centipede grass ( Eremochloa ophiuroides ) extract as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 피부질환 개선용 건강식품을 제공한다. The present invention also provides a health food for improving skin diseases, which comprises an organic solvent fraction prepared by further extracting a centipedragus extract with an organic solvent as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 피부질환 개선용 건강식품을 제공한다. The present invention also provides a health food for improving skin diseases, comprising an active fraction obtained by further fractionating a fraction of a centipedragus extract by column chromatography as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 피부질환 개선용 의약외품을 제공한다. In order to achieve the above object, the present invention provides a quasi-drug for skin disease improvement comprising Centipede grass ( Eremochloa ophiuroides ) extract as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 피부질환 개선용 의약외품을 제공한다. In addition, the present invention provides a quasi-drug for skin disease improvement comprising an organic solvent fraction prepared by further extracting a centipedragus extract with an organic solvent as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 피부질환 개선용 의약외품을 제공한다. In addition, the present invention provides a quasi-drug for skin disease improvement comprising an active fraction obtained by further fractionating the fraction of Sentifed glass extract by column chromatography as an active ingredient.
아울러, 본 발명은 샴푸, 비누, 린스 및 헤어토닉으로 구성된 군으로부터 선택된 어느 하나로 사용하는 피부질환 개선용 의약외품을 제공한다.
In addition, the present invention provides a quasi-drug for improving skin diseases, which is used as any one selected from the group consisting of shampoo, soap, rinse, and hair tonic.
본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획이 여드름균의 원인균인 표피 포도구균 및 프로피로니박테리움 아크네스, 및 비듬의 원인균인 말라세지아의 성장을 현저히 저해시킴으로서 새로운 천연 여드름 등을 포함한 미생물 유래의 피부질환을 효과적으로 예방, 치료 및 개선용 조성물의 유효성분으로 유용하게 사용될 수 있다.
The present invention relates to the use of Centipede grass ( Eremochloa ophiuroides extract, its fractions or the active fractions isolated from the fractions significantly inhibits the growth of Staphylococcus epidermidis and Propionibacterium acnes, causative bacteria of acne bacteria, and Malasejia, a causative agent of dandruff, The present invention can be effectively used as an effective ingredient of a composition for effectively preventing, treating and ameliorating a skin disease caused by microorganisms,
도 1은 센티페드그라스의 추출물, 이의 분획물 및 상기 분획물로부터 분리한 활성분획을 제조하는 과정을 나타낸 그림이다.
도 2는 여드름 원인균인 표피포도구균에 정제하지 않은 센티페드그라스 분획물을 다양한 농도로 처리하였을 때 결과를 나타낸 그림이다.
도 3은 여드름 원인균인 표피포도구균에 50% 메탄올로 정제한 센티페드그라스 분획물을 다양한 농도로 처리하였을 때 결과를 나타낸 그림이다.
도 4는 여드름 원인균인 표피포도구균에 70% 메탄올로 정제한 센티페드그라스 분획물을 다양한 농도로 처리하였을 때 결과를 나타낸 그림이다.
도 5는 여드름 원인균인 프로피로니박테리움 아크네스에 정제하지 않은 센티페드그라스 분획물을 다양한 농도로 처리하였을 때 결과를 나타낸 그림이다.
도 6은 여드름 원인균인 프로피로니박테리움 아크네스에 70% 메탄올로 정제한 센티페드그라스 분획물을 처리하였을 때 결과를 나타낸 그림이다.
도 7은 비듬의 원인균인 말라세지아에 정제하지 않은 센티페드그라스 분획물을 다양한 농도로 처리하였을 때 결과를 나타낸 그림이다.
도 8은 비듬의 원인균인 말라세지아에 50% 메탄올로 정제한 센티페드그라스 분획물을 다양한 농도로 처리하였을 때 결과를 나타낸 그림이다.
도 9는 비듬의 원인균인 말라세지아에 70% 메탄올로 정제한 센티페드그라스 분획물을 다양한 농도로 처리하였을 때 결과를 나타낸 그림이다.1 is a view showing a process for preparing an extract of Sentifedgrass, fractions thereof and active fractions isolated from the fractions.
Fig. 2 is a graph showing the effect of The results are shown in the case where the non-purified Centipede Grass fractions were treated at various concentrations.
FIG. 3 is a graph showing the results of treatment with various concentrations of the fraction of Sentifedgrass purified with 50% methanol in Staphylococcus epidermidis, a cause of acne.
FIG. 4 is a graph showing the results obtained by treating the streptococcus fraction purified with 70% methanol to various concentrations of Staphylococcus epidermidis, a cause of acne.
Fig. 5 is a graph showing the effect of The results are shown in the case where the non-purified Centipede Grass fractions were treated at various concentrations.
FIG. 6 is a graph showing the results of treatment of a fraction of Sentifedgrass purified with 70% methanol in Propionibacterium acnes, a causative agent of acne.
Fig. 7 is a graph showing the relationship between The results are shown in the case where the non-purified Centipede Grass fractions were treated at various concentrations.
FIG. 8 is a graph showing the results obtained when the fraction of Sentifedgrass purified with 50% methanol in Malassezia causing dandruff was treated at various concentrations.
FIG. 9 is a graph showing the results of treatment with various concentrations of the fraction of Sentipedgrass purified with 70% methanol in Malassezia causing dandruff.
이하, 본 발명을 상세히 설명한다.
Hereinafter, the present invention will be described in detail.
본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 피부질환 예방 및 치료용 약학적 조성물을 제공한다. The present invention relates to the use of Centipede grass ( Eremochloa ophiuroides ) as an active ingredient. The present invention also provides a pharmaceutical composition for preventing and treating skin diseases.
상기 센티페드그라스 추출물은 하기의 단계들을 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정하지 않는다: The centipedlass extract is preferably, but not exclusively, prepared by a process comprising the steps of:
1) 센티페드그라스에 추출용매를 가하여 추출하는 단계;1) extracting Sentipedgrass with an extraction solvent;
2) 단계 1)의 추출물을 식힌 후 여과하는 단계; 및2) cooling the extract of step 1) and filtering; And
3) 단계 2)의 여과한 추출물을 감압농축하는 단계.3) Concentrating the filtered extract of step 2) under reduced pressure.
상기 방법에 있어서, 단계 1)의 센티페드그라스는 재배한 것 또는 시판되는 것 등 제한 없이 사용할 수 있다. 상기 센티페드그라스는 잎, 줄기 또는 뿌리를 모두 이용할 수 있으나, 잎을 이용하는 것이 바람직하다.In the above method, the centipedegrass of step 1) may be used without limitation such as grown or commercially available. The centipedegrass may be a leaf, a stem, or a root, but leaves are preferably used.
상기 추출용매는 물, 알코올 또는 이들의 혼합물을 사용하는 것이 바람직하다. 상기 알코올로는 C1 내지 C4의 저급 알코올을 이용하는 것이 바람직하며, 저급 알코올로는 에탄올 또는 메탄올을 이용하는 것이 바람직하다. 추출방법으로는 진탕추출 또는 환류추출을 이용하는 것이 바람직하나 이에 한정하지 않는다. 상기 추출용매를 센티페드그라스 분량에 2 내지 10배 첨가하여 추출하는 것이 바람직하나 이에 한정하지 않는다. 추출온도는 50 내지 100℃인 것이 바람직하나 이에 한정하지 않는다. 또한, 추출시간은 2 내지 5일인 것이 바람직하나 이에 한정하지 않는다. 아울러, 추출 회수는 1 내지 3회인 것이 바람직하나 이에 한정하지 않는다. The extraction solvent is preferably water, alcohol or a mixture thereof. As the alcohol, C 1 to C 4 lower alcohols are preferably used, and as the lower alcohol, ethanol or methanol is preferably used. As the extraction method, it is preferable to use shaking extraction or reflux extraction, but it is not limited thereto. The extraction solvent is preferably added by 2 to 10 times the amount of the centipede glass, but not limited thereto. The extraction temperature is preferably 50 to 100 DEG C, but is not limited thereto. The extraction time is preferably 2 to 5 days, but is not limited thereto. The number of times of extraction is preferably 1 to 3 times, but is not limited thereto.
상기 방법에 있어서, 단계 3)의 감압농축은 진공감압농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정하지 않는다. 또한, 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조하는 것이 바람직하나 이에 한정하지 않는다.In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in step 3), but it is not limited thereto. The drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.
본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 피부질환 예방 및 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for skin disease prevention and treatment, which comprises an organic solvent fraction prepared by further extracting a centipedragus extract with an organic solvent as an active ingredient.
본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 피부질환 예방 및 치료용 약학적 조성물을 제공한다. The present invention provides a pharmaceutical composition for the prevention and treatment of skin diseases, which comprises an active fraction obtained by further fractionating a fraction of Sentifedgrax extract by column chromatography, as an active ingredient.
상기 센티페드그라스 추출물의 분획물 또는 상기 분획물로부터 분리한 활성분획은 하기의 단계들을 포함하는 제조방법에 의해 제조되는 것이 바람직하나 이에 한정하지 않는다:The fraction of the centipedlass extract or the active fraction isolated from the fraction is preferably, but not necessarily, prepared by a process comprising the steps of:
1) 센티페드그라스 추출물에 추가로 유기용매를 가하여 유기용매 분획물을 제조하는 단계; 및1) preparing an organic solvent fraction by adding an organic solvent to the centipede glass extract; And
2) 단계 1)의 분획물을 컬럼크로마토그래피를 실시하여 활성분획을 제조하는 단계.2) Performing column chromatography on the fraction of step 1) to produce an active fraction.
상기 방법에 있어서, 단계 1)의 유기용매는 n-헥산 또는 에틸아세테이트인 것이 바람직하나 이에 한정하지 않는다.In the above method, the organic solvent in step 1) is preferably, but not limited to, n-hexane or ethyl acetate.
상기 방법에 있어서, 상기 유기용매 분획물은 n-핵산으로 추출한 후 물층을 에틸아세테이트로 추출한 에틸아세테이트 분획물인 것이 바람직하나 이에 한정하지 않는다. In the above method, the organic solvent fraction is preferably an ethyl acetate fraction extracted with n-nucleic acid and a water layer extracted with ethyl acetate, but is not limited thereto.
상기 방법에 있어서, 단계 2)의 컬럼크로마토그래피는 실리카겔, 세파덱스, RP-18, 폴리아미드, 도요펄(Toyopearl) 및 XAD 수지로 이루어진 그룹으로부터 선택된 충진제를 이용한 컬럼크로마토그래피를 수행하여 활성분획을 분리 및 정제할 수 있다. 컬럼크로마토그래피는 필요에 따라 적절한 충진제를 선택하여 수차례 실시할 수 있다. In this method, the column chromatography of step 2) is carried out by column chromatography using a filler selected from the group consisting of silica gel, Sephadex, RP-18, polyamide, Toyopearl and XAD resin to obtain an active fraction Can be separated and purified. The column chromatography can be carried out several times by selecting an appropriate filler as necessary.
본 발명자들은 센티페드그라스의 에틸아세테이트 분획물을 Flex-ColumTM(3 ㎝ × 25 ㎝) 및 도요펄(Toyoperarl) HW-40(75 ㎛) 컬럼크로마토그래피에 흡착시키고 20, 50 또는 70% 메탄올 용출용매를 사용하여, 에틸아세테이트-20%메탄올, 에틸아세테이트-50%메탄올 및 에틸아세테이트-70%메탄올 활성분획을 얻었다.
The present inventors adsorbed the ethyl acetate fraction of Sentifedgrass onto a column of Flex-Colum ™ (3 cm × 25 cm) and Toyoperarl HW-40 (75 μm) column chromatography and eluted with 20, 50 or 70% methanol eluting solvent Ethyl acetate-20% methanol, ethyl acetate-50% methanol and ethyl acetate-70% methanol active fractions were obtained.
본 발명자들은 센티페드그라스 추출물의 농도에 따른 여드름균의 억제 효과를 알아보기 위하여 표피포도구균에 센티페드그라스 추출물의 농도(0.3125, 0.625, 1.25, 2.5, 5 및 10 ug/ml)로 정제하지 않은 센티페드그라스 분획물을 처리하였을 때 각각 1.75, 1.5, 2, 2, 2.75 및 2.75의 평균 면적을 나타내었고(도 2 및 표 5 참조), 각각을 50% 메탄올로 정제한 센티페드그라스 분획물을 처리하였을 때 1.75, 2, 2.125, 2.25, 1.375 및 3의 평균 면적을 나타내었으며(도 3 및 표 5 참조), 각각을 70% 메탄올로 정제한 센티페드그라스 분획물을 처리하였을 때 평균면적은 1.75, 1.5, 2, 2, 2.75 및 2.75로 나타났다(도 4 및 표 5 참조). 센티페드그라스 추출물이 표피 포도구균의 성장을 저해하는 것을 알 수 있었다.The inventors of the present invention found that the inhibitory effect of the extract of Centipede Grass on the inhibition of acne bacterium was not purified by the concentration of Sentifedgrass extract (0.3125, 0.625, 1.25, 2.5, 5 and 10 ug / ml) When Sentifedgrass fractions were treated, the average areas of 1.75, 1.5, 2, 2, 2.75 and 2.75 (see Figs. 2 and 5) were respectively treated with 50% methanol purified Centipede grass fractions (See FIG. 3 and Table 5), and the average area of the fraction treated with 70% methanol was 1.75, 1.5, 2, 2.125, 2.25, 1.375 and 3 2, 2, 2.75 and 2.75 (see Figs. 4 and 5). It was found that the centipedegrass extract inhibited the growth of Staphylococcus epidermidis.
또한, 본 발명자들은 센티페드그라스 추출물의 농도에 따른 여드름균의 억제 효과를 알아보기 위하여 프로피로니박테리움 아크네스에 센티페드그라스 메탄올 추출물 0.3125, 0.625, 1.25, 2.5, 5 및 10 ug/ml의 농도로 정제하지 않은 센티페드그라스 분획물을 처리하였을 때 각각 1.75, 1.5, 2, 2, 2.75 및 2.75의 평균 면적을 나타내었고(도 5 및 표 6 참조), 각각을 70% 메탄올로 정제한 센티페드그라스 분획물을 처리하였을 때 평균면적은 0, 0.25, 0.3, 1, 2.2 및 3.5를 나타냈다(도 6 및 표 6 참조). 센티페드그라스 추출물이 프로피로니박테리움 아크네스의 성장을 저해하는 것을 알 수 있었다.In order to investigate the inhibitory effect of the extract of Centipede Grass Extract on the inhibition of acne bacterium, the present inventors measured the inhibitory effect of Centipede Grass Extract on inhibition of acne bacterium in a concentration of 0.3125, 0.625, 1.25, 2.5, 5 and 10 ug / ml (Fig. 5 and Table 6), respectively, when treated with the non-purified Centipedegrass fractions (Fig. 5 and Table 6) When the fractions were treated, the mean areas were 0, 0.25, 0.3, 1, 2.2 and 3.5 (see FIG. 6 and Table 6). It was found that the extract of Sentifedgrass inhibited the growth of Propionibacterium acnes.
본 발명자들은 센티페드그라스 추출물의 농도에 따른 비듬균의 억제 효과를 알아보기 위하여 말라세지아에 센티페드그라스 메탄올 추출물 0.3125, 0.625, 1.25, 2.5, 5 및 10 ug/ml의 농도로 정제하지 않은 센티페드그라스 분획물을 처리하였을 때 각각 1.75, 1.5, 2, 2, 2.75 및 2.75의 평균 면적을 나타내었고(도 7 및 표 7 참조), 각각을 50% 메탄올로 정제한 센티페드그라스 분획물을 처리하였을 때 1, 1.75, 1.75, 2, 2.25 및 1.75의 평균 면적을 나타내었으며(도 8 및 표 7 참조), 각각을 70% 메탄올로 정제한 센티페드그라스 분획물을 처리하였을 때 평균면적은 0.5, 0.75, 1.5, 1.5, 2 및 2를 나타냈다(도 9 및 표 7 참조). 센티페드그라스 추출물이 말라세지아의 성장을 저해하는 것을 알 수 있었다.
In order to examine the inhibitory effect of dandruff on the concentration of the centipedragus extract, the present inventors measured the inhibitory effect of the centipede extract on the concentration of the centipede extract, 0.3125, 0.625, 1.25, 2.5, 5 and 10 ug / ml, When the fractions of the plants treated with the fraction of Grass showed an average area of 1.75, 1.5, 2, 2, 2.75 and 2.75 (see FIG. 7 and Table 7) (See FIGS. 8 and 7), the average area of the treated fraction treated with 70% methanol was 0.5, 0.75, 1.5, 1.5, 1.75, 1.5, 2 and 2 (see Figs. 9 and 7). It was found that the centipedegrass extract inhibited the growth of malassezia.
따라서, 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획이 여드름균 및 비듬균의 성장을 현저하게 저해시킴으로서 피부질환 예방 및 치료에 효과적인 약학적 조성물로서 유용하게 사용될 수 있다.
Accordingly, the centipede glass extract, its fractions, or the active fractions isolated from the fractions significantly inhibits the growth of acne bacteria and dandruff, thereby being useful as a pharmaceutical composition effective for prevention and treatment of skin diseases.
본 발명의 상기 피부 질환은 여드름 또는 비듬인 것이 바람직하나, 이에 한정되지 않는다.
The skin diseases of the present invention are preferably acne or dandruff, but are not limited thereto.
본 발명의 약학적 조성물은 통상적으로 사용되는 부형제, 붕해제, 감미제, 활택제, 향미제 등을 추가로 포함할 수 있으며, 통상적인 방법에 의해 정제, 캅셀제, 산제, 과립제, 현탁제, 유제, 시럽제, 기타 액제로 제형화될 수 있다.The pharmaceutical composition of the present invention may further contain commonly used excipients, disintegrants, sweeteners, lubricants, flavors and the like, and may be formulated into tablets, capsules, powders, granules, suspensions, Syrups, and other liquid preparations.
구체적으로 본 발명의 약학적 조성물은 경구 투여용 제형, 예를 들면 정체, 트로치제(troches), 로젠지(lozenge), 수용성 또는 우성현탁액, 조제분말 또는 과립, 에멀젼, 하드 또는 소프트 캡슐, 시럽 또는 엘릭시르제(elixirs)로 제제화된다. 정제 및 캡슐 등의 제형으로 제제하기 위해 락토오스, 사카로오스, 솔비톨, 만니톨, 전분, 아밀로펙틴, 셀롤로오스 또는 젤라틴과 같은 결합제, 디칼슘 포스페이트와 같은 부형제, 옥수수 전분 또는 고구마 전분과 같은 붕해제, 스테아르산 마그네슘, 스테아르산 칼슘, 스테아릴푸마르산 나트륨 또는 폴리에틸렌글리콜 왁스와 같은 윤활유가 함유된다. 캡슐제형의 경우는 상기에서 언급한 물질 이외에도 지방유와 같은 액체 담체를 함유한다.Specifically, the pharmaceutical compositions of the present invention can be formulated for oral administration, for example, as tablets, troches, lozenges, aqueous or aqueous suspensions, prepared powders or granules, emulsions, hard or soft capsules, It is formulated into elixirs. Binders such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, celluloses or gelatin, excipients such as dicalcium phosphate, disintegrants such as corn starch or sweet potato starch, and disintegrants such as stearic acid Magnesium stearate, calcium stearate, sodium stearyl fumarate, or polyethylene glycol wax. In the case of a capsule formulation, in addition to the above-mentioned substances, a liquid carrier such as fatty oil is contained.
또한, 본 발명의 약학적 조성물은 경구 또는 비경구 투여할 수 있으며, 비경구 투여시 피하주사, 정맥주사, 근육내 주사 또는 흉부내 주사 주입방식을 선택하는 것이 바람직하다. 비경구 투여용 제형으로 제제화하기 위해서는 본 발명의 센티페드그라스 추출물, 이의 분획물 또는 분획물의 활성분획을 안정제 또는 완충제와 함께 물에서 혼합하여 현탁액으로 제조하고 이를 앰플 또는 바이알의 단위 투여형으로 제제한다.In addition, the pharmaceutical composition of the present invention can be administered orally or parenterally, and it is preferable to select subcutaneous injection, intravenous injection, intramuscular injection, or intra-thoracic injection injection method for parenteral administration. In order to formulate the formulation for parenteral administration, the active fraction of the centipede glass extract, fraction or fraction thereof of the present invention is mixed with water with a stabilizer or a buffer to prepare a suspension, which is formulated into a unit dosage form of ampoule or vial.
본 발명에 따른 유효성분의 투여량은 체내에서 활성성분의 흡수도, 불활성화율 및 배설속도, 환자의 연령, 성별 및 상태, 치료할 질병의 중증 정도에 따라 적절히 선택되나, 경구 투여제의 경우 일반적으로 성인에게 1일에 체중 1 ㎏당 본 발명의 추출물을 0.0001 ~ 500 ㎎의 양으로 1회 내지 수회 나누어 투여할 수 있으며, 0.001 ~ 100 ㎎의 양으로 투여하는 것이 바람직하다.
The dosage of the active ingredient according to the present invention is appropriately selected depending on the degree of absorption, inactivation rate and excretion rate of the active ingredient in the body, the age, sex and condition of the patient, and severity of the disease to be treated. The extract of the present invention may be administered to an adult in an amount of 0.0001-500 mg per 1 kg of body weight per day, preferably in an amount of 0.001-100 mg per one kg of body weight.
본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 피부질환 개선용 화장료 조성물을 제공한다. The present invention relates to the use of Centipede grass ( Eremochloa ophiuroides ) extract as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 피부질환 개선용 화장료 조성물을 제공한다. The present invention also provides a cosmetic composition for skin disease improvement comprising an organic solvent fraction prepared by further extracting a centipedragus extract with an organic solvent as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 피부질환 개선용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for skin disease improvement comprising an active fraction obtained by further fractionating a fraction of Sentifed glass extract by column chromatography as an active ingredient.
본 발명의 화장료 조성물에 있어서 상기 피부질환은 여드름 또는 비듬인 것이 바람직하나, 이에 한정되지 않는다.
In the cosmetic composition of the present invention, the skin disease is preferably acne or dandruff, but is not limited thereto.
상기 화장료 조성물은, 예를 들면 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀), 비이온형의 소낭 분산제의 형태, 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태로 제공될 수 있다. 또한, 포말(foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 제조될 수 있다.The cosmetic composition may be in the form of a solution, a gel, a solid or a paste anhydrous product, an emulsion obtained by dispersing an oil phase in water, a suspension, a microemulsion, a microcapsule, a microgranule or an ionic (liposome) A cream, a skin, a lotion, a powder, an ointment, a spray, or a cone stick. It can also be prepared in the form of a foam or an aerosol composition further containing a compressed propellant.
또한, 상기 화장료 조성물은 본 발명의 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.The cosmetic composition may further contain, in addition to the active fraction isolated from the centipede glass extract of the present invention, the fraction thereof or the fraction, a fat substance, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, Surfactants, water, ionic or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic Or lipophilic active agents, lipid vesicles, or any other ingredients commonly used in cosmetics.
본 발명의 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획을 함유하는 화장료 조성물에 있어서, 통상적으로 함유되는 화장료 조성물에 본 발명의 추출물이 1 내지 15 중량%, 바람직하게는 2 내지 10 중량%의 양으로 첨가될 수 있다.In the cosmetic composition containing the centipede glass extract of the present invention, the fraction thereof or the active fraction isolated from the fraction, the extract of the present invention is added to the cosmetic composition usually contained in an amount of 1 to 15% by weight, preferably 2 to 10% % ≪ / RTI > by weight.
본 발명의 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획을 피부 외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한, 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다.
When the centipede glass extract of the present invention, the fraction thereof, or the active fraction isolated from the fraction is used as an external preparation for skin, it may further contain a fatty substance, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, Stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, barrier agents, wetting agents, essential oils, dyes, pigments, Hydrophilic or lipophilic active agents, lipid vesicles or any other ingredient conventionally used in external preparations for skin. In addition, the components can be introduced in amounts commonly used in the dermatology field.
본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 피부질환 예방 및 치료용 피부 외용제를 제공한다. The present invention relates to the use of Centipede grass ( Eremochloa ophiuroides ) extract as an active ingredient for the prevention and treatment of skin diseases.
또한, 본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 피부질환 예방 및 치료용 피부 외용제를 제공한다. The present invention also provides an external preparation for skin for preventing and treating skin diseases, which comprises an organic solvent fraction prepared by further extracting a centipede glass extract with an organic solvent as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 피부질환 예방 및 치료용 피부 외용제를 제공한다. The present invention also provides an external preparation for skin for the prevention and treatment of skin diseases, which comprises an active fraction obtained by further fractionating a fraction of Sentifedgrax extract by column chromatography.
본 발명의 피부 외용제에 있어서 상기 피부질환은 여드름 및 비듬인 것이 바람직하나, 이에 한정되지 않는다.
In the external preparation for skin of the present invention, the skin diseases are preferably acne and dandruff, but are not limited thereto.
피부질환을 효과적으로 치료하기 위해서는 적합한 외용제형을 선택하는 것이 중요하다. 피부질환을 치료하기 위해 센티페드그라스 추출물을 적당히 희석하여 피부에 직접 도포할 수도 있으며, 본 발명의 피부질환 치료용 약학적 조성물이 환부에 효과적으로 적용될 수 있도록 연고제로 제조할 수 있다. 상기 연고제는 본 발명의 피부질환 치료용 약학적 조성물을 무기물질과 배합한 다음, 이를 지용성 기제로 코팅하여 제조한다. 상기 무기물질은 항균성, 소염효과, 표피재생 효과 등이 우수한 소재를 사용하는 것이 바람직하고, 이들의 구체적인 예로는 산화아연, 탄산아연, 산화철 등이 있다. 또한, 수용성 물질인 본 발명의 피부질환 치료용 약학적 조성물을 안전하게 함침 할 수 있는 세라믹 담체를 추가로 사용하는 것이 바람직하다. 상기 세라믹 담체로는 제올라이트, 활석, 석고, 모려분 및 이들의 혼합물이 바람직하게 사용된다. 이러한 세라믹 담체는 수용성 성분의 함침성이 우수하여 피부에 수용성 성분의 공급을 원활히 할 수 있다.
In order to effectively treat skin diseases, it is important to select a suitable external preparation. In order to treat skin diseases, the centipedragus extract may be suitably diluted and directly applied to the skin. Alternatively, the pharmaceutical composition for treating skin diseases of the present invention may be prepared as an ointment so as to be effectively applied to the affected part. The ointment is prepared by combining a pharmaceutical composition for treating skin diseases of the present invention with an inorganic substance and then coating it with a liposoluble base. The inorganic material is preferably a material having excellent antimicrobial activity, anti-inflammatory effect, epidermal regeneration effect, etc. Specific examples thereof include zinc oxide, zinc carbonate, iron oxide and the like. In addition, it is preferable to further use a ceramic carrier capable of safely impregnating a pharmaceutical composition for treating skin diseases of the present invention which is a water-soluble substance. As the ceramic carrier, zeolite, talc, gypsum, mortar and mixtures thereof are preferably used. Such a ceramic carrier is excellent in the impregnation property of the water-soluble component, so that the water-soluble component can be smoothly supplied to the skin.
본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 피부질환 개선용 건강식품을 제공한다. The present invention relates to the use of Centipede grass ( Eremochloa ophiuroides ) extract as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 피부질환 개선용 건강식품을 제공한다. The present invention also provides a health food for improving skin diseases, which comprises an organic solvent fraction prepared by further extracting a centipedragus extract with an organic solvent as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 피부질환 개선용 건강식품을 제공한다. The present invention also provides a health food for improving skin diseases, comprising an active fraction obtained by further fractionating a fraction of a centipedragus extract by column chromatography as an active ingredient.
본 발명의 건강식품에 있어서 상기 피부질환은 여드름 및 비듬인 것이 바람직하나, 이에 한정되지 않는다.
In the health food of the present invention, the skin diseases are preferably acne and dandruff, but are not limited thereto.
본 발명의 건강식품은 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.The health food of the present invention may be added to the centipede glass extract, its fraction or the active fraction isolated from the fraction as it is, or may be used together with other food or food ingredients, and may be suitably used according to a conventional method.
상기 식품의 종류에는 특별한 제한은 없다. 상기 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.
There is no particular limitation on the kind of the food. Examples of the food to which the centipedegrass extract, the fraction thereof, or the active fraction isolated from the fraction can be added include meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gum, ice cream , Various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.
아울러, 본 발명은 센티페드그라스(Centipede grass, Eremochloa ophiuroides) 추출물을 유효성분으로 함유하는 피부질환 개선용 의약외품을 제공한다. In addition, the present invention provides a quasi-drug for skin disease improvement comprising Centipede grass ( Eremochloa ophiuroides ) extract as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물을 추가적으로 유기용매로 추출하여 제조된 유기용매 분획물을 유효성분으로 함유하는 피부질환 개선용 의약외품을 제공한다. In addition, the present invention provides a quasi-drug for skin disease improvement comprising an organic solvent fraction prepared by further extracting a centipedragus extract with an organic solvent as an active ingredient.
또한, 본 발명은 센티페드그라스 추출물의 분획물을 추가적으로 컬럼크로마토그래피로 분리한 활성분획을 유효성분으로 함유하는 피부질환 개선용 의약외품을 제공한다. In addition, the present invention provides a quasi-drug for skin disease improvement comprising an active fraction obtained by further fractionating the fraction of Sentifed glass extract by column chromatography as an active ingredient.
본 발명의 의약외품에 있어서 상기 피부질환은 여드름 및 비듬인 것이 바람직하나, 이에 한정되지 않는다.In the quasi-drug of the present invention, the skin disease is preferably acne and dandruff, but is not limited thereto.
본 발명의 의약외품은 샴푸,비누, 린스 및 헤어토닉으로 구성된 것이 바람직하나, 이에 한정되지 않는다.
The quasi-drug of the present invention is preferably composed of shampoo, soap, rinse, and hair tonic, but is not limited thereto.
본 발명의 의약외품은 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획을 그대로 첨가하거나 다른 의약외품 또는 의약외품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.The quasi-drug of the present invention can be used as a centipede glass extract, a fraction thereof, or an active fraction isolated from the fraction as it is or in combination with other quasi-drugs or quasi-drugs, and can be suitably used according to a conventional method.
상기 의약외품의 종류에는 특별한 제한은 없다. 상기 센티페드그라스 추출물, 이의 분획물 또는 상기 분획물로부터 분리한 활성분획을 첨가할 수 있는 모든 의약외품을 포함한다.
There is no particular limitation on the kind of the quasi-drug. The centipede glass extract, the fraction thereof, or all the quasi-drugs capable of adding an active fraction isolated from the fraction.
이하, 본 발명을 실시예, 실험예, 비교예 및 제조예에 의하여 상세히 설명한다. Hereinafter, the present invention will be described in detail with reference to Examples, Experimental Examples, Comparative Examples and Preparation Examples.
단, 하기 실시예, 실험예, 비교예 및 제조예는 본 발명을 구체적으로 예시하는 것이며, 본 발명의 내용이 실시예, 실험예, 비교예 및 제조예에 의해 한정되는 것은 아니다.
However, the following Examples, Experimental Examples, Comparative Examples and Preparation Examples illustrate the present invention concretely, and the contents of the present invention are not limited by Examples, Experimental Examples, Comparative Examples and Preparation Examples.
<< 실시예Example 1> 1> 센티페드그라스Sentiped Grass 추출물의 제조 Preparation of extract
<1-1> <1-1> 센티페드그라스Sentiped Grass 메탄올 추출물의 제조 Preparation of methanol extract
센티페드그라스 종자를 일본의 Fukukaen Nursery and Blub co. Ltd로부터 수입하여 한국원자력연구원 정읍 방사선과학연구소의 포장에서 증식하여 센티페드그라스 잎 시료를 채취하였다. 채취한 잎 시료는 -80℃에 보관하여 사용하였다. 센티페드그라스 잎 5 ㎏을 100% 메탄올(MeOH) 20 ℓ를 첨가하여 믹서기로 마쇄한 후 상온에서 3일간 침지시켜 얻은 추출물을 50℃에서 감압 농축하여 210 g의 센티페드그라스 메탄올 추출물을 수득하였다.
The centipede grass seeds were collected from Fukukaen Nursery and Blub co. Ltd., And propagated in the packaging of the Korea Atomic Energy Research Institute 's Jeong - eup Radiation Research Institute and collected samples of centipede grass leaves. Leaf samples were stored at -80 ° C. 5 kg of Centipede grass leaf was added with 20 L of 100% methanol (MeOH), ground with a blender, immersed at room temperature for 3 days, and then concentrated under reduced pressure at 50 캜 to obtain 210 g of a centipede glass methanol extract.
<1-2> <1-2> 센티페드그라스Sentiped Grass 에탄올 추출물의 제조 Preparation of ethanol extract
센티페드그라스 종자를 일본의 Fukukaen Nursery and Blub co. Ltd로부터 수입하여 한국원자력연구원 정읍 방사선과학연구소의 포장에서 증식하여 센티페드그라스 잎 시료를 채취하였다. 채취한 잎 시료는 -80℃에 보관하여 사용하였다. 센티페드그라스 잎 5 ㎏을 100% 에탄올(EtOH) 20 ℓ를 첨가하여 믹서기로 마쇄한 후 상온에서 3일간 침지시켜 얻은 추출물을 50℃에서 감압 농축하여 203 g의 센티페드그라스 에탄올 추출물을 수득하였다.
The centipede grass seeds were collected from Fukukaen Nursery and Blub co. Ltd., And propagated in the packaging of the Korea Atomic Energy Research Institute 's Jeong - eup Radiation Research Institute and collected samples of centipede grass leaves. Leaf samples were stored at -80 ° C. 5 kg of centipedegrass leaves were added with 20 L of 100% ethanol (EtOH), ground with a blender, immersed in the liquid at room temperature for 3 days, and concentrated under reduced pressure at 50 DEG C to obtain 203 g of a centipede glass ethanol extract.
<1-3> <1-3> 센티페드그라스Sentiped Grass 물 추출물의 제조 Preparation of water extract
센티페드그라스 종자를 일본의 Fukukaen Nursery and Blub co. Ltd로부터 수입하여 한국원자력연구원 정읍 방사선과학연구소의 포장에서 증식하여 센티페드그라스 잎 시료를 채취하였다. 채취한 잎 시료는 -8℃에 보관하여 사용하였다. 센티페드그라스 잎 5 ㎏을 물 20 ℓ를 첨가하여 믹서기로 마쇄한 후 상온에서 3일간 침지시켜 얻은 추출물을 50℃에서 감압 농축하여 198 g의 센티페드그라스 물 추출물을 수득하였다.
The centipede grass seeds were collected from Fukukaen Nursery and Blub co. Ltd., And propagated in the packaging of the Korea Atomic Energy Research Institute 's Jeong - eup Radiation Research Institute and collected samples of centipede grass leaves. The collected leaf samples were stored at -8 ° C. 20 ℓ of water was added to 5 ㎏ of centipedegrass, and the mixture was ground with a blender and then immersed at room temperature for 3 days. The extract was concentrated under reduced pressure at 50 캜 to obtain 198 g of centipede water extract.
<< 실시예Example 2> 2> 센티페드그라스Sentiped Grass 분획물의Fraction 제조 Produce
<2-1> n-<2-1> n- 헥산Hexane 분획물의Fraction 제조 Produce
상기 실시예 <1-1>에서 수득한 센티페드그라스 메탄올 추출물을 유기용매를 사용하여 극성에 따른 분획을 실시하였다.The centipede glass methanol extract obtained in Example <1-1> was fractionated according to the polarity using an organic solvent.
<2-2> 에틸아세테이트 <2-2> Ethyl acetate 분획물의Fraction 제조 Produce
<도 1>과 같이, 감압농축한 메탄올 추출물을 물에 현탁한 후, 저극성 용매인 n-헥산으로 먼저 추출한 후에 물층을 다시 에틸아세테이트(EtOAc)로 분획하였다. As shown in <Fig. 1>, the methanol extract concentrated under reduced pressure was suspended in water and then extracted first with n-hexane as a low polarity solvent. Then, the water layer was fractionated again with ethyl acetate (EtOAc).
<2-3> 물 <2-3> Water 분획물의Fraction 제조 Produce
상기 실시예 <2-2>에서 n-헥산 및 에틸아세테이트(EtOAc)로 분획한 후 물에 의한 가용 분획물을 마지막으로 수득하였다. 각 용매추출 분획을 감압농축하여 건조시킨 후, 에틸아세테이트 분획물(21 g)을 얻었다.
In Example < 2-2 > in the above Example, fractionation with n-hexane and ethyl acetate (EtOAc) was carried out and finally a soluble fraction with water was obtained. The solvent-extracted fractions were concentrated under reduced pressure and dried to obtain an ethyl acetate fraction (21 g).
<< 실시예Example 3> 3> 센티페드그라스Sentiped Grass 활성분획의 제조 Production of active fractions
<3-1> 에틸아세테이트-20% 메탄올 <3-1> Ethyl acetate-20% methanol 분획물의Fraction 제조 Produce
상기 <실시예 2>의 에틸아세테이트 분획물을 20% 메탄올을 용출용매로 사용하여 Flex-Colum TM(3 ㎝×25 ㎝)과 Toyoperarl HW-40(75 ㎛)를 사용하여 컬럼크로마토그래피를 실시하여 활성분획물을 수득하였다. 에틸아세테이트-20% 메탄올 9.41 g의 활성분획을 수득하였다.
The ethyl acetate fraction of Example 2 was dissolved in Flex-Colum TM (3 cm x 25 cm) using 20% methanol as elution solvent, Column chromatography was performed using Toyoperarl HW-40 (75 占 퐉) to obtain an active fraction. Ethyl acetate-20% methanol 9.41 g of active fraction.
<3-2> 에틸아세테이트-50% 메탄올 ≪ 3-2 > Ethyl acetate-50% methanol 분획물의Fraction 제조 Produce
상기 <실시예 2>의 에틸아세테이트 분획물을 50% 메탄올을 용출용매로 사용하여 Flex-Colum TM(3 ㎝×25 ㎝)과 Toyoperarl HW-40(75 ㎛)를 사용하여 컬럼크로마토그래피를 실시하여 활성분획물을 수득하였다. 에틸아세테이트-50% 메탄올 5.74 g의 활성분획을 수득하였다.
The ethyl acetate fraction of Example 2 was dissolved in 50% methanol to give Flex-ColumTM(3 cm x 25 cm) and Column chromatography was performed using Toyoperarl HW-40 (75 占 퐉) to obtain an active fraction. Ethyl acetate-50% methanol 5.74 g of active fraction was obtained.
<3-3>에틸아세테이트-70% 메탄올 <3-3> Ethyl acetate-70% methanol 분획물의Fraction 제조 Produce
상기 <실시예 2>의 에틸아세테이트 분획물을 70% 메탄올을 용출용매로 사용하여 Flex-Colum TM(3 ㎝×25 ㎝)과 Toyoperarl HW-40(75 ㎛)를 사용하여 컬럼크로마토그래피를 실시하여 활성분획물을 수득하였다. 에틸아세테이트-70% 메탄올 1 g의 활성분획을 수득하였다.
The ethyl acetate fraction of Example 2 was dissolved in Flex-Colum TM (3 cm x 25 cm) using 70% methanol as elution solvent, Column chromatography was performed using Toyoperarl HW-40 (75 占 퐉) to obtain an active fraction. Ethyl acetate - 1 g of active fraction with 70% methanol was obtained.
<< 실시예Example 4> 여드름균 및 비듬균의 배양 4> Cultivation of Acne Bacteria and Strain
<4-1> 여드름균<4-1> Acne bacteria
표피 포도구균(taphylococcus epidermidis, Winslow and Winslow, Evans)은 여드름을 발생하는 중요한 균으로서 박테리아이고, 하기 [표 1]의 트립티케이즈 소이(Trypticase soy)배지에서 37℃로 배양하였다.
Taphylococcus epidermidis (Winslow and Winslow, Evans) is an important bacterial strain that causes acne and is cultured in a Trypticase soy medium (Table 1) at 37 ° C.
또한, 프로피로니 박테리움 아크네스(Propionibacterium acnes, Gilchrist, Douglas and Gunter) 여드름을 발생하는 중요한 균으로서 박테리아이고, 하기 [표 2]의 크로스티리디아(clostridia)가 첨가된 배지에서 37℃로 배양하였다.
In addition, Propionibacterium acnes (Gilchrist, Douglas and Gunter) is a bacterial strain which is an important microorganism causing acne and is cultured at 37 ° C in a medium supplemented with the clostridia shown in Table 2 below .
<4-2> 비듬균<4-2>
말라세지아(Malassezia furfur, Robin, Baillon)는 비듬을 유발하는 효모로서, 하기 [표 3]의 1% 올리브 오일을 추가한 배지 37에서 30℃로 배양하였다.
Malassezia furfur (Robin, Baillon) was a dandruff-inducing yeast, which was cultured at 30 ° C in medium 37 supplemented with 1% olive oil of the following [Table 3].
<< 실험예Experimental Example 1> 1> 센티페드그라스Sentiped Grass 추출물 또는 이의 Extract or its 분획물의Fraction 여드름균에 대한 항균활성 Antimicrobial activity against acne bacteria
<1-1> <1-1> 센티페드그라스Sentiped Grass 추출물 또는 이의 Extract or its 분획물의Fraction 농도에 따른 Depending on concentration 표피포도구균의Staphylococcus aureus 억제 효과 측정 Measurement of inhibitory effect
표피 포도구균(taphylococcus epidermidis)은 여드름의 원인이 되는 균이다. 표피 포도구균을 실시예 <4-1>의 조건에서 24시간 배양하였다. 배양한 균액 2 ㎖를 원심분리기로 세포를 분리한 후, PBS 완충용액 200 ㎕를 넣어 보텍스(votex)를 이용하여 잘 섞어주고, 배지에 고르게 도말하였다. 멸균된 디스크(Disk, 3M paper)를 동일한 크기(지름 1cm)로 자른 후에 하기와 같이 동일한 간격을 두고 배치하였다. 디스크에 하기 [표 4]의 농도별 센티페드그라스 용액을 10 ul 씩 5번 떨어뜨려 점 분석(Spot assay)을 하기 위하여 건조시켰고, 표피 포도구균을 37℃배양온도에서 배양하며 3시간 별로 확인하였다.Taphylococcus epidermidis is a cause of acne. Staphylococcus epidermidis was cultured for 24 hours under the conditions of Example <4-1>. Cells were separated by centrifugation in 2 ml of the cultured bacterial suspension, 200 μl of PBS buffer was added thereto, mixed well using a vortex, and uniformly plated on a medium. Sterilized disks (Disk, 3M paper) were cut to the same size (1 cm in diameter) and then placed at the same interval as described below. The centipedegrass solution of each concentration in Table 4 was dropped on the
그 결과, 실시예 <1-1>의 센티페드그라스 메탄올 추출물 0.3125, 0.625, 1.25, 2.5, 5 및 10 ug/ml의 농도로 처리하였을 때 각각 1.75, 1.5, 2, 2, 2.75 및 2.75의 평균 면적을 나타내었고(표 5 및 도 2), 실시예 <3-2>의 센티페드그라스 50% 메탄올 분획물을 처리하였을 때 평균면적은 1.75, 2, 2.125, 2.25, 1.375 및 3의 평균 면적을 나타내었으며(표 5 및 도 3), 실시예 <3-2>의 센티페드그라스 70% 메탄올 분획물을 처리하였을 때 평균면적은 1.75, 1.5, 2, 2, 2.75 및 2.75를 나타냈다(표 5 및 도 4). 따라서 센티페드그라스 추출물 또는 분획물이 표피 포도구균의 성장을 저해하는 것이 확인하였다.
As a result, it was found that the treatment with the concentrations of 0.3125, 0.625, 1.25, 2.5, 5 and 10 ug / ml of the centipede glass methanol extract of Example <1-1> resulted in an average of 1.75, 1.5, 2, 2, 2.75 and 2.75 (Table 5 and FIG. 2). When the 50% methanol fraction of Sentifedgrass of Example <3-2> was treated, the average area was 1.75, 2, 2.125, 2.25, 1.375 and 3 (Table 5 and Fig. 3), the average areas of the centipedegrass 70% methanol fractions of Example <3-2> were 1.75, 1.5, 2, 2.75 and 2.75, respectively ). Therefore, it was confirmed that the extract of Centipedgrass or the fraction inhibited the growth of Staphylococcus epidermidis.
<1-2> <1-2> 센티페드그라스Sentiped Grass 추출물 또는 분획물의 농도에 따른 Depending on the concentration of the extract or fraction 프로피로니박테리움Propionibacterium 아크네스의 억제 효과 측정 Measuring the inhibitory effect of acnes
프로피오니박테리움 아크네스(Propionibacterium acnes, P. acnes)는 여드름의 원인이 되는 균이다. 센티페드그라스 추출물의 농도에 따른 프로피로니박테리움 아크네스의 억제 효과를 알아보기 위하여 스팟 분석을 하였다. 구체적으로, 프로피로니박테리움 아크네스를 실시예 <4-1>의 조건에서 24시간 배양하였다. 배양한 균액 2 ㎖를 원심분리기로 세포를 분리한 후, PBS 완충용액 200 ㎕를 넣어 보텍스(votex)를 이용하여 잘 섞어주고, 배지에 고르게 도말하였다. 멸균된 디스크(Disk)를 동일한 크기(지름 1 cm)로 자른 후에 하기와 같이 동일한 간격을 두고 배치하였다. 디스크에 상기 [표 4]의 농도별 센티페드그라스 용액을 10 ul 씩 5번 떨어뜨려 스팟 분석을 하기 위하여 건조시켰고, 프로피로니박테리움 아크네스를 37℃에서 배양하며 3시간 마다 확인하였다.Propionibacterium acnes (P. acnes) is a causative agent of acne. Spat analysis was carried out to investigate the inhibitory effect of Propidium bacterium acnes on the concentration of centipedegrass extract. Specifically, Propionibacterium acnes were cultured for 24 hours under the conditions of Example <4-1>. Cells were separated by centrifugation in 2 ml of the cultured bacterial suspension, 200 μl of PBS buffer was added thereto, mixed well using a vortex, and uniformly plated on a medium. Sterilized disks were cut to the same size (1 cm in diameter) and then placed at the same interval as described below. 10 μl of Centipede Grass solution at the concentration of [Table 4] was dropped on the
그 결과, 실시예 <1-1>의 센티페드그라스 메탄올 추출물을 0.3125, 0.625, 1.25, 2.5, 5 및 10 ug/ml의 농도로 처리하였을 때 각각 1.75, 1.5, 2, 2, 2.75 및 2.75의 평균 면적을 나타내었고(표 6 및 도 5), 실시예 <3-3>의 센티페드그라스 70% 메탄올 분획물을 처리하였을 때 평균면적은 0, 0.25, 0.3, 1, 2.2 및 3.5를 나타냈다(표 6 및 도 6). As a result, when the centipede glass methanol extract of Example <1-1> was treated at the concentrations of 0.3125, 0.625, 1.25, 2.5, 5 and 10 ug / ml, the concentrations of 1.75, 1.5, 2, 2.75 and 2.75 (Table 6 and FIG. 5), and when the 70% methanol fraction of Sentifedgrass of Example <3-3> was treated, the mean areas were 0, 0.25, 0.3, 1, 2.2 and 3.5 6 and FIG. 6).
따라서 센티페드그라스 추출물 또는 분획물이 프로피로니박테리움 아크네스의 성장을 저해하는 것이 확인하였다.
Thus, it was confirmed that the centipedlass extract or the fraction inhibited the growth of Propionibacterium acnes.
<< 실험예Experimental Example 2> 2> 센티페드그라스Sentiped Grass 추출물 또는 이의 Extract or its 분획물의Fraction 농도에 따른 비듬균에 대한 항균 활성 측정 Measurement of antimicrobial activity against dandruff by concentration
말라세지아는 비듬의 원인이 되는 균이다. 센티페드그라스 추출물 또는 이의 분획물의 농도에 따른 말라세지아의 억제 효과를 알아보기 위하여 스팟 분석을 하였다. 구체적으로, 말라세지아를 실시예 <4-2>의 조건에서 24시간 배양하였다. 배양한 균액 2 ㎖를 원심분리기로 세포를 분리한 후, PBS 완충용액 200 ㎕를 넣어 보텍스(votex)를 이용하여 잘 섞어주고, 배지에 고르게 도말하였다. 멸균된 디스크(Disk)를 동일한 크기(지름 1 cm)로 자른 후에 하기와 같이 동일한 간격을 두고 배치하였다. 디스크에 상기 [표 4]의 농도별 센티페드그라스 용액을 10 ul 씩 5번 떨어뜨려 스팟 분석을 하기 위하여 건조시켰고, 말라세지아를 30℃에서 배양하며 3시간마다 확인하였다.Malassezia is a cause of dandruff. Spat analysis was carried out to investigate the inhibitory effect of Malassezia on the concentration of the centipedegrass extract or its fractions. Specifically, malassezia was cultured for 24 hours under the conditions of Example <4-2>. Cells were separated by centrifugation in 2 ml of the cultured bacterial suspension, 200 μl of PBS buffer was added thereto, mixed well using a vortex, and uniformly plated on a medium. Sterilized disks were cut to the same size (1 cm in diameter) and then placed at the same interval as described below. 10 μl of Centipede glass solution of each concentration of [Table 4] was dropped on the
그 결과, 실시예 <1-1>의 센티페드그라스 메탄올 추출물을 0.3125, 0.625, 1.25, 2.5, 5 및 10 ug/ml의 농도로 처리하였을 때 각각 1.75, 1.5, 2, 2, 2.75 및 2.75의 평균 면적을 나타내었고(표 7 및 도 7), 실시예 <3-2>의 세디페트그라스 50% 분획물 처리하였을 때 평균면적은 1, 1.75, 1.75, 2, 2.25 및 1.75의 평균 면적을 나타내었으며(표 7 및 도 8), 실시예 <3-3>의 세디페트그라스 70% 분획물 처리하였을 때 평균면적은 0.5, 0.75, 1.5, 1.5, 2 및 2를 나타냈다(표 7 및 도 9). 따라서 센티페드그라스 추출물 또는 이의 분획물이 말라세지아의 성장을 저해하는 것이 확인하였다.
As a result, when the centipede glass methanol extract of Example <1-1> was treated at the concentrations of 0.3125, 0.625, 1.25, 2.5, 5 and 10 ug / ml, the concentrations of 1.75, 1.5, 2, 2.75 and 2.75 (Table 7 and FIG. 7), and when the 50% fraction of Sedipetgrass of Example <3-2> was treated, the average area was 1, 1.75, 1.75, 2, 2.25 and 1.75 (Table 7 and FIG. 8) and 70% fractions of Sedipetgrass of Example <3-3>, the average areas were 0.5, 0.75, 1.5, 1.5, 2 and 2 (Table 7 and FIG. 9). Therefore, it was confirmed that the centipedragus extract or its fractions inhibited the growth of malassezia.
<< 제조예Manufacturing example 1> 약제의 제조 1> Manufacture of Pharmaceuticals
<1-1> 시럽제의 제조≪ 1-1 > Preparation of syrup preparation
상기 <실시예 3>의 센티페드그라스 에틸아세테이트-20% 메탄올 활성분획을 유효성분으로 함유하는 시럽제는 하기 [표 8]의 조성과 같이 제조하였다.Syrup preparations containing the active fractions of Sentifedgrass Ethyl Acetate-20% methanol of Example 3 as an active ingredient were prepared according to the composition shown in Table 8 below.
<1-2> 정제의 제조<1-2> Preparation of tablets
상기 <실시예 3>의 센티페드그라스 에틸아세테이트-20% 메탄올 활성분획을 유효성분으로 함유하는 정제는 하기 [표 9]의 조성과 같이 제조하였다.
Tablets containing the active fraction of Sentifedgrass ethyl acetate-20% methanol of Example 3 as an active ingredient were prepared as shown in Table 9 below.
상기 <실시예 3>의 에틸아세테이트-20% 메탄올 활성분획 250 중량부, 락토오스 175.9 중량부, 감자전분 180 중량부 및 콜로이드성 규산 32 중량부와 혼합하였다. 상기 혼합물에 10% 젤라틴 용액을 첨가시킨 후, 분쇄하여 14 매쉬체를 통과시켰다. 이것을 건조하고 여기에 감자전분 160 중량부, 활석 50 중량부 및 스테아린산 마그네슘 5 중량부를 첨가하여 얻은 혼합물을 정제로 제조하였다.
250 parts by weight of ethyl acetate-20% methanol active fraction of Example 3, 175.9 parts by weight of lactose, 180 parts by weight of potato starch and 32 parts by weight of colloidal silicic acid. 10% gelatin solution was added to the mixture, followed by pulverization and passed through a 14-mesh sieve. This was dried, to which 160 parts by weight of potato powder, 50 parts by weight of talc and 5 parts by weight of magnesium stearate were added, and the resulting mixture was purified.
<< 제조예Manufacturing example 2> 2> 화장료의Cosmetic 제조 Produce
<2-1> 유연 화장수의 제조<2-1> Production of Flexible Lotion
상기 실시예 <1-2>의 센티페드그라스 에탄올 추출물을 유효성분으로 함유하는 유연 화장수는 하기 [표 10]과 같이 제조하였다.
The softened lotion containing the centipede grass ethanol extract of Example <1-2> as an active ingredient was prepared as shown in Table 10 below.
<2-2> 영양 크림의 제조<2-2> Preparation of nutritional cream
상기 실시예 <1-2>의 센티페드그라스 에탄올 추출물을 유효성분으로 함유한 영양크림은 하기 [표 11]의 조성과 같이 제조하였다.
The nutritional cream containing the centipede grass ethanol extract of Example <1-2> as an active ingredient was prepared according to the composition shown in Table 11 below.
<제조예 3> 피부 외용제의 제조 ≪ Preparation Example 3 > Preparation of external preparation for skin
<3-1> 지용성(W/O 제형) 연고<3-1> Liposoluble (W / O formulation) Ointment
실시예 <3-2>의 아세테이트-70 % 메탄올 센티페드그라스 분획물 0.01 - 10.0%Acetate-70% methanol pentape grass fraction of Example < 3-2 > 0.01 - 10.0%
스테아릴 알콜 7.0%Stearyl alcohol 7.0%
스테아린산 2.2%Stearic acid 2.2%
스쿠알렌 3.4%Squalene 3.4%
옥틸두오데칸올 5.0%Octyl dodecanol 5.0%
올리브유 6.0m%Olive oil 6.0m%
글리세린모노하우릴 지방산 에스텔 10.0%Glycerin monoauric fatty acid ester 10.0%
이소프로필 아디페이트 2.0%Isopropyl adipate 2.0%
테고 0.3%Tego 0.3%
카복실비닐폴리머 3.0%Carboxyl vinyl polymer 3.0%
프로필렌 글리콜 5.0%Propylene glycol 5.0%
코직산 0.05%Kojic acid 0.05%
알파-케토글루타민산 0.2%Alpha-keto glutamic acid 0.2%
시스테인 0.2%Cysteine 0.2%
파라벤류 0.3%Parabens 0.3%
멸균 정제수 또는 0.02M 인산 또는 완충용액 잔량Sterile purified water or 0.02 M phosphate or buffer solution balance
상기의 성분을 혼합한 후, 통상의 방법에 따라 지용성 연고를 제조하였다.
After mixing the above components, a fat-soluble ointment was prepared according to a conventional method.
<3-2> 친수성(O/W형) 연고<3-2> Hydrophilic (O / W type) ointment
실시예 <3-2>의 아세테이트-70 % 메탄올 센티페드그라스 분획물 0.01 - 10.0%Acetate-70% methanol pentape grass fraction of Example < 3-2 > 0.01 - 10.0%
백색바세린 25.0%White vaseline 25.0%
스테아릴알콜 20.0%Stearyl alcohol 20.0%
프로필렌글리콜 12.0%Propylene glycol 12.0%
프로필렌미스스틴산 0.1%Propylene misstatin 0.1%
소디움 글리세린 모노라우렐 0.2%Sodium glycerin monolaurate 0.2%
폴리옥시에틸렌경화피마자유 4.0%Polyoxyethylene hardened castor oil 4.0%
베타인 함유 양이온성 유화제 0.2%Betaine-containing cationic emulsifier 0.2%
모노스테아린산글리세린에스텔 0.1%Glycerin monostearate 0.1%
파라옥시안식향산프로필 0.1%0.1% paraoxybenzoic acid propylate
정제수 잔량Purified water balance
상기의 성분을 혼합한 후, 통상의 방법에 따라 친수성 연고를 제조하였다.
After mixing the above components, a hydrophilic ointment was prepared according to a conventional method.
<3-3> 크림<3-3> Cream
실시예 <3-2>의 아세테이트-70 % 메탄올 센티페드그라스 분획물 0.01 - 10.0%Acetate-70% methanol pentape grass fraction of Example < 3-2 > 0.01 - 10.0%
유동파라핀 6.0%Liquid paraffin 6.0%
스쿠알란 4.0%Squalane 4.0%
소르비탄세스퀴올레이트 0.5%0.5% sorbitan sesquioleate
폴리솔베이트 60 1.5%Polysorbate 60 1.5%
밀랍 10.0%Beeswax 10.0%
카프필릭/카프릭프리글리세라이드 5.0%Cappolic / capric triglyceride 5.0%
부틸렌글리콜 6.0%Butylene glycol 6.0%
프리에탄올아민 3.0%Free ethanolamine 3.0%
방부제 2.0%Preservatives 2.0%
향료 미량Fragrance
정제수 잔량Purified water balance
상기의 조성으로 센티페드그라스 추출물을 함유하는 크림을 통상의 방법에 따라 제조할 수 있었다.
The cream containing the centipedragus extract in the above composition could be prepared by a conventional method.
<< 제조예Manufacturing example 4> 건강식품의 제조 4> Manufacture of health food
<4-1> 밀가루 식품의 제조<4-1> Production of flour food
상기 실시예 <1-3>의 센티페드그라스 물 추출물 0.5 ~ 5.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하였다.
0.5-5.0 parts by weight of the centipedglass water extract of Example <1-3> was added to wheat flour, and the mixture was used to prepare bread, cake, cookies, crackers and noodles.
<4-2> <4-2> 스프soup 및 육즙( And juicy ( graviesgravies )의 제조)
상기 실시예 <1-3>의 센티페드그라스 물 추출물 0.1 ~ 5.0 중량부를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.
0.1 to 5.0 parts by weight of the centipedglass water extract of Example <1-3> was added to the soup and the juice to prepare a health promotion meat product, noodle soup and juice.
<4-3> 그라운드 <4-3> Ground 비프(ground beef)의Beef 제조 Produce
상기 실시예 <1-3>의 센티페드그라스 물 추출물 10 중량부를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.
10 parts by weight of the centipede water extract of Example <1-3> was added to the ground beef to prepare ground beef for health promotion.
<4-4> 유제품(<4-4> Dairy products ( dairydairy productsproducts )의 제조)
상기 실시예 <1-3>의 센티페드그라스 물 추출물 5 ~ 10 중량부를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.
5-10 parts by weight of the centipedglass water extract of Example <1-3> was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
<4-5> <4-5> 선식의Solar 제조 Produce
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.
검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.
상기 실시예 <1-3>의 센티페드그라스 물 추출물을 진공 농축기에서 감압농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The centipede water extract of Example <1-3> was concentrated under reduced pressure in a vacuum concentrator, dried by spraying and dried in a hot air drier, and pulverized to a size of 60 mesh with a pulverizer to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 실시예 <1-3>의 센티페드그라스 물 추출물을 다음의 비율로 배합하여 제조하였다.The above-prepared cereals, seeds and centipede water extract of Example <1-3> were prepared in the following proportions.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
실시예 <1-3>의 추출물(3 중량부),The extract (3 parts by weight) of Example <1-3>,
영지(0.5 중량부),(0.5 part by weight),
지황(0.5 중량부)
(0.5 parts by weight)
<< 제조예Manufacturing example 5> 의약외품의 제조 5> Manufacture of quasi-drugs
<5-1> 샴푸의 제조<5-1> Production of shampoo
상기 실시예 <3-2> 에틸아세테이트-50% 메탄올 분획물 5 ~ 30 중량%The <3-2> ethyl acetate-50% methanol fraction of 5-30 wt%
라우릴황산 암모늄 10.0 중량% Ammonium lauryl sulfate 10.0 wt%
폴리옥시에틸렌 아우릴황산나트륨 5.0 중량%5.0 weight% sodium polyoxyethylene < RTI ID = 0.0 >
코코아미도프로필레타인 5.0 중량%5.0% by weight < RTI ID = 0.0 >
라우로일미리스틸리에탄올아미드 3.0 중량%3.0% by weight of lauroyl myristyl ethanolamide
에틸렌글리콜디스테아레이트 1.0 중량%1.0% by weight of ethylene glycol distearate
폴리 퀘터늄-7 1.0 중량%Polyquaternium-7 1.0 wt%
청색 1호 0.0001 중량%Blue No. 1 0.0001 wt%
황색 4호 0.0004 중량%Yellow No. 4 0.0004 wt%
파라옥시안식향산메틸 0.1 중량%0.1% by weight of methyl paraoxybenzoate
향료 0.5 중량%0.5% by weight fragrance
구연산 0.2 중량%Citric acid 0.2 wt%
정제수 잔부Purified water balance
상기의 조성으로 센티페드그라스 추출물을 함유하는 샴푸를 통상의 방법에 따라 제조할 수 있었다.
A shampoo containing a centipedragus extract in the above composition could be prepared by a conventional method.
<5-2> 비누의 제조<5-2> Production of soap
상기 실시예 <3-2> 에틸아세테이트-50% 메탄올 분획물 24 중량%Example 3-2 ethyl acetate-50% methanol fraction 24%
글리세린 0.2 중량%0.2% by weight of glycerin
폴리에틸렌 글리콜 0.8 중량%0.8% by weight of polyethylene glycol
호호바유 0.3 중량%Jojoba oil 0.3 wt%
세탄올 0.15 중량%0.15 wt% cetanol
비누베이스 72.3 중량%Soap base 72.3 wt%
토코페놀 아세테이트 0.2 중량%0.2% by weight of tocopherol acetate
상기의 조성으로 센티페드그라스 추출물을 함유하는 비누를 통상의 방법에 따라 제조할 수 있었다.
A soap containing a centipede glass extract in the above composition could be prepared by a conventional method.
<5-3> 린스의 제조<5-3> Manufacture of rinse
상기 실시예 <1-2> 에틸아세테이트 에탄올 추출물 10 중량%<Example 1-2> Ethyl acetate ethanol extract: 10 wt%
라우릴황산나트륨(30%) 20 중량%20% by weight of sodium lauryl sulfate (30%)
폴리옥시에틸렌라우릴황산나트륨(30%) 20 중량%20% by weight of polyoxyethylene laurylsulfate (30%),
야자유지방산디에탄올아미드 3 중량%3% by weight of palm oil fatty acid diethanolamide
프로필렌글리콜 0.25 중량%0.25% by weight of propylene glycol
색소 적량Pigment amount
구연산 적량Citric acid quantity
정제수 잔부Purified water balance
상기의 조성으로 센티페드그라스 추출물을 함유하는 린스를 통상의 방법에 따라 제조할 수 있었다.
A rinse containing the centipede glass extract in the above composition could be prepared according to a conventional method.
<5-4> 헤어토닉의 제조<5-4> Manufacture of hair tonic
상기 실시예 <1-2> 에틸아세테이트 에탄올 추출물 10 중량%<Example 1-2> Ethyl acetate ethanol extract: 10 wt%
디소듐이디티에이 0.05 중량%Disodium diithia 0.05 wt%
판테놀 0.10 중량%Panthenol 0.10 wt%
폴리쿼터늄-1 0.30 중량%Polyquaternium-1 0.30 wt%
그리세릴 스테아레이트 1.50 중량%1.50 wt% glyceryl stearate
폴리소르베이트 60 0.50 중량%Polysorbate 60 0.50 wt%
글리세릴 스테아레이트 0.40 중량%0.40 wt% of glyceryl stearate
디메치콘 2.00 중량%Dimethicone 2.00 wt%
미네랄 오일 2.00 중량%Mineral oil 2.00 wt%
세틸알코올 2.00 중량%Cetyl alcohol 2.00 wt%
향료 적량Fragrance quantity
방부제 적량Antiseptic
정제수 잔부 Purified water balance
상기의 조성으로 센티페드그라스 추출물을 함유하는 헤어토닉을 통상의 방법에 따라 제조할 수 있었다.A hair tonic containing the centipedragus extract in the above composition could be prepared by a conventional method.
Claims (17)
A pharmaceutical composition for prevention and treatment of acne or dandruff comprising water of Centipede grass ( Eremochloa ophiuroides ), C 1 - C 2 lower alcohol or a mixed solvent extract thereof as an active ingredient.
The pharmaceutical composition according to claim 1, wherein the lower alcohol is ethanol or methanol.
A pharmaceutical composition for preventing and treating acne or dandruff comprising an organic solvent fraction prepared by extracting a centipede-grass extract with an organic solvent as an active ingredient.
The pharmaceutical composition for preventing and treating acne or dandruff according to claim 4, wherein the organic solvent is n-hexane or ethyl acetate.
[Claim 5] The pharmaceutical composition according to claim 4, wherein the fraction is an ethyl acetate fraction obtained by extracting Centipedgrass extract with n-nucleic acid and then extracting the water layer with ethyl acetate.
A pharmaceutical composition for the prevention and treatment of acne or dandruff comprising an active fraction which is obtained by further adsorbing an ethyl acetate fraction of a centipedlass extract to column chromatography and using methanol as an eluting solvent as an active ingredient.
A cosmetic composition for treating acne or dandruff comprising the water of centipede water of claim 1 , a lower alcohol of C 1 - C 2 or a mixed solvent thereof, a fraction of claim 4 or an active fraction of claim 7 as an active ingredient.
An external preparation for skin for the prevention and treatment of acne or dandruff comprising, as an active ingredient, the water of the centipede glass of claim 1 , the lower alcohol of C 1 - C 2 or the mixed solvent thereof, the fraction of claim 4 or the active fraction of claim 7.
A health food for treating acne or dandruff comprising the water of centipede water of claim 1 , a lower alcohol of C 1 - C 2 or a mixed solvent thereof, a fraction of claim 4 or an active fraction of claim 7 as an active ingredient.
A quasi-drug for the treatment of acne or dandruff comprising the water of centipede water of claim 1 , a lower alcohol of C 1 to C 2 or a mixed solvent thereof, a fraction of claim 4 or an active fraction of claim 7 as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120080623A KR101398549B1 (en) | 2012-07-24 | 2012-07-24 | A composition for skin disease improvement comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120080623A KR101398549B1 (en) | 2012-07-24 | 2012-07-24 | A composition for skin disease improvement comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140015761A KR20140015761A (en) | 2014-02-07 |
| KR101398549B1 true KR101398549B1 (en) | 2014-05-27 |
Family
ID=50265063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120080623A KR101398549B1 (en) | 2012-07-24 | 2012-07-24 | A composition for skin disease improvement comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101398549B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104001038B (en) * | 2014-06-23 | 2017-01-18 | 陈智辉 | External preparation for treating acne |
| CN104189680B (en) * | 2014-09-04 | 2017-04-05 | 中南大学湘雅医院 | A kind of oral agents for treating facial inflammatory dermatoses |
| KR101967338B1 (en) * | 2016-12-12 | 2019-04-10 | 한국원자력연구원 | Pharmaceutical composition for preventing or treating of alopecia comprising extract or fractions of eremochloa ophiuroides as an active ingredient |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110054747A (en) * | 2009-11-18 | 2011-05-25 | 한국원자력연구원 | A composition for skin wrinkle improvement comprising extracts or fractions of eremochloa ophiuroides as an active ingredient |
-
2012
- 2012-07-24 KR KR1020120080623A patent/KR101398549B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110054747A (en) * | 2009-11-18 | 2011-05-25 | 한국원자력연구원 | A composition for skin wrinkle improvement comprising extracts or fractions of eremochloa ophiuroides as an active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140015761A (en) | 2014-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101864409B1 (en) | Antibacterial or antifungal composition comprising oriental medicine extract and microbial ferment extract as an active ingredient | |
| KR102194315B1 (en) | Antioxidant or skin microbiome balance cosmetic composition comprising centella asiatica fermented extract fermented by inoculating lactobacillus rhamnosus strain | |
| KR101634668B1 (en) | Cosmetic composition comprising fermented extract of mistletoe for anti-oxidation or whitening | |
| KR102166279B1 (en) | Composition for Anti-Oxidant, Anti-Bacterial and Anti-Inflammatory Effect Comprising Plant Complex Extracts as Active Ingredient | |
| KR20100072865A (en) | A composition for the prevention, improvement or treatment of acne vulgaris comprising the mixture of extract of phellodendron amurense rupr, houttuynia cordata, paeonia lactiflora pall, agrimonia pilosa ledeb, and glycyrrhiza uralensis fisch as an effective ingredient | |
| KR102207995B1 (en) | Composition for Anti-microbial, Anti-inflammation, and Skin Hydration Property Comprising Fermented Extract of Momordica charantia as Active Ingredient | |
| KR20150013994A (en) | Composition for hair or scalp treatment comprising fermented black garlic residue and method of preparing the same | |
| KR20190036298A (en) | A composition for improving inflammatory skin disease containing evergreen woody species | |
| KR101398549B1 (en) | A composition for skin disease improvement comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient | |
| KR102247810B1 (en) | Composition Comprising Mixed Culture Strain of Lactobacillus sp. SDCM 1003 and SDCM 1105, Culture Fluid, or Culture Fluid Extract thereof as Active Ingredient | |
| KR20240004199A (en) | Antibacterial composition containing extract or fractions of Prunus pendula for. ascendens | |
| KR102228257B1 (en) | Composition for anti-inflammation or anti-acne comprising extract of Immature Citrus Fruit, Curcuma longa and citrus blossom honey | |
| KR102172224B1 (en) | compositions containing fermented extract of Panax ginseng | |
| KR20120010439A (en) | An antibacterial and antifungal composition containing the extracts and fractions of Hosta capitata as active ingredient | |
| KR102158134B1 (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
| KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
| KR102594733B1 (en) | Cosmetic composition for improving melasma, freckles, whitenings and wrinkle comprising extract of fermented chestnut inner shell, angelica dahurica, portulace oleracea, armeniacae and mori dadicis cortex and preparation method thereof | |
| KR102367027B1 (en) | Antimicrobial composition comprising Hydrangea petiolaris extracts or fractions thereof as effective component | |
| KR20180088051A (en) | Compositions for decreasing sebum and improving acne comprising extracts of Pinus densiflora leaf, Artemisia annua and Citrus junos fruit | |
| KR20180017974A (en) | Cosmetic composition for preventing or treating acne comprising combined herbal extracts | |
| KR101363028B1 (en) | A cosmetic composition for the prevention, improvement or treatment of acne vulgaris comprising the mixture of extract of Melissa officinalis, Citrus bergamia, leaves of Mentha arvensis, Eclipta prostrata and Hovenia dulcis Thunb | |
| EP0717613B1 (en) | Stable composition containing wheat sprout juice and process for producing it | |
| JP2021004214A (en) | Combinational fermented product | |
| KR102379678B1 (en) | Antibacterial composition containing extract or fractions of fermented black radish | |
| KR102546957B1 (en) | Anti-inflammatory and antibacterial composition comprising a Cedrela sinensis extract as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20180406 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20190328 Year of fee payment: 6 |